Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11655352 | 1.00 | ALDH1A1 (0.32) | ALDH1A1CYP2D6SMN1; SMN2NPSR1GLO1 | |
| SCHEMBL11655353 | 1.00 | ALDH1A1 (0.32) | ALDH1A1CYP2D6SMN1; SMN2NPSR1GLO1 | |
| SCHEMBL2335326 | 0.87 | NPSR1 (0.35) | ALDH1A1CYP2D6SMN1; SMN2NPSR1GLO1 | |
| SCHEMBL11659065 | 0.85 | SOAT1 (0.35) | ALDH1A1NPSR1GLO1 | |
| SCHEMBL11654683 | 0.85 | CES2 (0.39) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL11654680 | 0.85 | CES2 (0.39) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL18936313 | 0.85 | ALDH1A1 (0.30) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL18936312 | 0.85 | ALDH1A1 (0.30) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL1549869 | 0.85 | ALDH1A1 (0.30) | ALDH1A1CYP2D6SMN1; SMN2 | |
| SCHEMBL5186529 | 0.85 | ALDH1A1 (0.30) | ALDH1A1CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762377-B1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | UNIV CORNELL (US) | 2025-08-20 | — | — | EP | disclosed |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | CORNELL UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| EP-3762377-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | Cook, Timothy, H. (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE | 2020-12-31 | — | — | US | disclosed |
| WO-2019173790-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND MEDICAL USES THEREOF | HLA TIMOTHY (US) | 2019-09-12 | — | — | WO | disclosed |
| CN-107759585-A | A kind of isoquinoline compound and its Pharmaceutical composition and the application as antiviral drugs | 银杏树药业(苏州)有限公司 | 2018-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407339-A1 | PYRIDINONE- AND PYRIDAZINONE-BASED COMPOUNDS AND USES THEREOF | PTGER1, LOXL1, COL1A1 | ALDH1A1 421/4885CYP2D6 154/4885SMN1; SMN2 3979/4885 |
| US-11964960-B2 | Pyridinone- and pyridazinone-based compounds and uses thereof | PTGER1, LOXL1, COL1A1 | ALDH1A1 421/4885CYP2D6 154/4885SMN1; SMN2 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.